MapLight Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
40.1%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$4.60next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Topline Results from Phase 2 VISTA (Alzheimer's Disease Psychosis) Trial | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
ZEPHYR Phase 2 Schizophrenia Trial Enrollment Quarterly307.0
IRIS Phase 2 Autism Spectrum Disorder Trial Enrollment Quarterly161.0
Cash, Cash Equivalents and Investments Quarterly395.2MTarget: Sufficient to fund operations through 2027
Watch Items
- Topline data readout for Phase 2 ZEPHYR trial (ML-007C-MA in schizophrenia)Trigger: Efficacy (PANSS total score change at Week 5) and safety/tolerability profileAction: Evaluate clinical efficacy versus approved muscarinic agonists (e.g., Cobenfy) and determine Phase 3 trial design
- Topline data readout for Phase 2 IRIS trial (ML-004 in autism spectrum disorder)Trigger: Improvement in social communication deficits and irritability symptomsAction: Assess clinical viability and formulate future development or licensing strategies for ML-004
- CFO Leadership TransitionTrigger: Appointment of a permanent Chief Financial Officer following the separation of Vishwas SetiaAction: Monitor corporate governance stability and ensure seamless financial reporting under interim CFO Jonathan Gillis
Research as of 19 Jun 2026